This is a Special Purpose Acquisition Company (SPAC) — a blank check company with no operations, revenue, or identified acquisition target. The company's sole purpose is to find and acquire a private business, taking it public through a transaction called a Business Combination. The SPAC raised $253M in its January 2026 IPO, with all proceeds held in trust until a deal closes or the company liquidates. The management team, led by CEO Arghavan Di Rezze, has a stated preference for healthcare targets but can pursue any sector or geography. The SPAC must complete a Business Combination by January 2028 or return funds to shareholders. The business model centers on the Sponsor's Founder Shares, acquired at a nominal cost, which gain value only if a deal closes — creating a strong incentive to transact. Public shareholders are protected by a redemption right at roughly $10.00 per share. The management team has prior SPAC experience through the Inflection Point franchise, having previously completed deals with Intuitive Machines and USA Rare Earth, though both deals saw very high redemption rates. Post-combination stock performance across prior deals has been mixed. Key advisors are simultaneously involved in a separate SPAC, Inflection Point Acquisition Corp. III, which raises potential conflicts around deal flow allocation.